Biosimilars: Innovator Pharmaceutical Products

Biosimilars is a Biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved "innovative" versions of original products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. This session also finds place for all the Biosimilar Exhibitors associated with the field of Biosimilar and Biologics. 2014 was a banner year for orphan drugs, which are drugs that treat "rare" diseases/disorders affecting fewer than 200,000 people in the U.S. A total of 41 new molecular entities (NMEs) and biologics (BLAs) were approved by the FDA in 2014 - 15 of those were approved in December alone (11 in final two weeks.

 

  • Biotechnology medicinal products for different drugs
  • Challenges faced in developing Biosimilars
  • Future of Biosimilars
  • Biopharmaceuticals development
  • Lyophilization of Biosimilars
  • Next generation Biosimilars

Related Conference of Biosimilars: Innovator Pharmaceutical Products

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal

Biosimilars: Innovator Pharmaceutical Products Conference Speakers

Recommended Sessions

Related Journals

Are you interested in